📊 EQ Key Takeaways
Is Equillium, Inc. (EQ) a Good Investment?
Equillium is a pre-commercial stage pharmaceutical company with severe cash burn, negative profitability across all metrics, and deteriorating operational efficiency despite modest revenue growth. While the company maintains strong liquidity with $33.1M cash and a fortress balance sheet, current burn rate of $19.6M annually and negative margins of -45%+ indicate the company is years away from sustainable operations without significant clinical success or capital raises.
Equillium shows adequate near-term financial stability, with cash of $33.12M, very low balance-sheet strain, and strong current liquidity at 10.85x. However, the business remains deeply unprofitable, with negative operating margin, negative free cash flow, and weak returns on equity and assets, which makes the recent revenue growth low quality unless it converts into sustained operating leverage. Fundamentally, the company looks more like a cash-funded development-stage operation than a self-sustaining enterprise.
Why Buy Equillium, Inc. Stock? EQ Key Strengths
- Strong liquidity position with $33.1M cash against only $3.6M liabilities
- Low leverage with 0.25x debt-to-equity ratio providing financial flexibility
- Revenue growth of 13.9% YoY showing some commercial traction despite pre-profitability stage
- Improving EPS trend with 39.5% YoY improvement in diluted EPS loss
- Strong liquidity, with cash representing most of total assets and current and quick ratios both at 10.85x
- Low reported leverage relative to equity, with debt/equity of 0.25x and limited total liabilities
- Revenue increased 13.9% year over year and diluted EPS improved, indicating some operating progress
EQ Stock Risks: Equillium, Inc. Investment Risks
- Massive negative cash burn of $19.6M annually with no path to profitability visible
- Net margin of -45.3% and operating margin of -47.9% indicate losses exceed revenues
- Cash runway of approximately 1.7 years at current burn rate without additional revenue growth
- Pharmaceutical sector execution risk with clinical pipeline success critical to viability
- Negative ROE of -60.2% and ROA of -54.0% showing severe capital inefficiency
- Operating expenses far exceed revenue, requiring major operational restructuring or breakthrough product success
- Profitability remains very weak, with operating margin of -47.9% and net margin of -45.3%
- Free cash flow is deeply negative at -$19.62M, implying continued cash burn and possible future financing needs
- Returns on capital are poor, with ROE of -60.2% and ROA of -54.0%, suggesting the asset base is not generating economic value
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate trajectory
- Revenue growth acceleration and product commercialization progress
- Operating expense management and path to breakeven timeline
- Clinical trial results and regulatory milestones for pipeline programs
- Cash runway and timing/terms of any future capital raises
- Quarterly operating cash burn and cash runway
- Whether revenue growth meaningfully narrows operating and net losses
Equillium, Inc. (EQ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.85x current ratio provides a solid financial cushion.
EQ Profit Margin, ROE & Profitability Analysis
EQ vs Healthcare Sector: How Equillium, Inc. Compares
How Equillium, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Equillium, Inc. Stock Overvalued? EQ Valuation Analysis 2026
Based on fundamental analysis, Equillium, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Equillium, Inc. Balance Sheet: EQ Debt, Cash & Liquidity
EQ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Equillium, Inc.'s revenue has grown significantly by 161% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
EQ Revenue Growth, EPS Growth & YoY Performance
EQ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $12.2M | -$7.0K | $0.00 |
| Q2 2025 | $13.9M | $468.0K | $0.01 |
| Q1 2025 | $10.7M | -$2.7M | $-0.08 |
| Q3 2024 | $8.9M | -$7.0K | $0.00 |
| Q2 2024 | $9.1M | $468.0K | $0.01 |
| Q1 2024 | $8.9M | -$2.7M | $-0.08 |
| Q3 2023 | $8.9M | -$3.3M | $-0.11 |
| Q2 2023 | $9.1M | -$3.3M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Equillium, Inc. Dividends, Buybacks & Capital Allocation
EQ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Equillium, Inc. (CIK: 0001746466)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EQ
What is the AI rating for EQ?
Equillium, Inc. (EQ) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EQ's key strengths?
Claude: Strong liquidity position with $33.1M cash against only $3.6M liabilities. Low leverage with 0.25x debt-to-equity ratio providing financial flexibility. ChatGPT: Strong liquidity, with cash representing most of total assets and current and quick ratios both at 10.85x. Low reported leverage relative to equity, with debt/equity of 0.25x and limited total liabilities.
What are the risks of investing in EQ?
Claude: Massive negative cash burn of $19.6M annually with no path to profitability visible. Net margin of -45.3% and operating margin of -47.9% indicate losses exceed revenues. ChatGPT: Profitability remains very weak, with operating margin of -47.9% and net margin of -45.3%. Free cash flow is deeply negative at -$19.62M, implying continued cash burn and possible future financing needs.
What is EQ's revenue and growth?
Equillium, Inc. reported revenue of $41.1M.
Does EQ pay dividends?
Equillium, Inc. does not currently pay dividends.
Where can I find EQ SEC filings?
Official SEC filings for Equillium, Inc. (CIK: 0001746466) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EQ's EPS?
Equillium, Inc. has a diluted EPS of $-0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EQ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Equillium, Inc. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EQ stock overvalued or undervalued?
Valuation metrics for EQ: ROE of -60.2% (sector avg: 15%), net margin of -45.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EQ stock in 2026?
Our dual AI analysis gives Equillium, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EQ's free cash flow?
Equillium, Inc.'s operating cash flow is $-19.6M, with capital expenditures of $4.0K. FCF margin is -47.7%.
How does EQ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -45.3% (avg: 12%), ROE -60.2% (avg: 15%), current ratio 10.85 (avg: 2).